Key Details
Price
$7.21Annual ROE
-303.20%Beta
0.22Events Calendar
Next earnings date:
Feb 7, 2025Recent quarterly earnings:
Oct 21, 2024Recent annual earnings:
Apr 10, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 3, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the second half and reporting in the Fourth Quarter of 2025 BERKELEY, Calif. and MAINZ, Germany, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the launch of eAArly DETECT 2, a U.S. feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a population of approximately 2,000 patients, all of average risk, to validate the industry leading results of previous feasibility studies, which included average risk and identified risk patients.
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, Sept.
BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
FAQ
- What is the ticker symbol for Mainz Biomed BV?
- Does Mainz Biomed BV pay dividends?
- What sector is Mainz Biomed BV in?
- What industry is Mainz Biomed BV in?
- What country is Mainz Biomed BV based in?
- When did Mainz Biomed BV go public?
- Is Mainz Biomed BV in the S&P 500?
- Is Mainz Biomed BV in the NASDAQ 100?
- Is Mainz Biomed BV in the Dow Jones?
- When was Mainz Biomed BV's last earnings report?
- When does Mainz Biomed BV report earnings?
- Should I buy Mainz Biomed BV stock now?